Comparison Between Different Lines of Antiviral Combination Therapies Against Hepatitis C Virus Genotype 4 In Egyptian Patients

Abstract

Hepatitis C virus (HCV) infection in one of worldwide chief causes chronic liver illness. The morbidity and mortality of this global infection are growing. Directly acting antivirals (DAAs) are a new era in treating HCV and considered the key of its management. This study was an open label clinical study, comparing the different lines of antiviral combination therapies against HCV in Egyptian patients as regards efficacy & safety. It was conducted on 1000 HCV chronically infected patients. Patients were collected from in Electricity hospital during period from May 2015 till Dec 2017. Out of 1737 patients who underwent initial evaluation, 531 patients were not eligible for therapy. The total number of patients eligible for antiviral treatment was 1206, 1000 of them started the treatment, while 206 patients did not start it. 995 patients completed the treatment program while 5 patients only did not complete it due to SAEs or death.